Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

A new study shows promising results for treating certain cancers with immunotherapy and completely avoiding surgery, ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.

Some people with early-stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...

During a major phase III trial, pembrolizumab combined with standard treatment kept cancer at bay for an average of 60 months ...

“She’s an example of this emerging face of cancer that's really quite challenging and quite alarming,” Deignan said.

Scientists discover how to rouse the immune system around "cold" tumors, making them vulnerable to cancer-killing immune ...

A new spit test for prostate cancer which can be done at home may be better than current testing methods, a study suggests. Experts have developed a simple saliva test which analyses genetic ...